State Street Holds 5% Of Geron Without Seeking To Influence Its Control
The holding comes against a quarterly profit, a trailing-year loss and a discontinued blood-cancer trial.
State Street reported a 5% stake in Geron, which sells the blood-cancer drug RYTELO, in a passive ownership disclosure filed Tuesday. The institution said its shares were held through ordinary business activity, rather than to change or influence the company's control.
Nearly 32 Million Shares
State Street reported beneficial ownership of 31,896,515 common shares, with September 30 as the date of the ownership event. The 5% figure uses the disclosure's Rule 13d-3 ownership basis.
The institution shared authority to sell or otherwise dispose of the entire holding and shared voting authority over 30,180,644 shares. Its certification distinguished that ownership from a position intended to influence control.
A Profit Beside Longer-Period Losses
Geron reported third-quarter revenue of $60.2 million and net income of $1.4 million. Its net margin reached 2.2%, compared with a negative 39.0% in the same quarter a year earlier.
The longer view still showed a net loss of $47.8 million on revenue of $217.5 million over the trailing twelve months. The quarterly profit therefore sits alongside losses across that broader reporting period.
Geron's IMpactMF trial was discontinued, adding a clinical-development setback to that uneven financial picture. The company had a market value of $642 million as of 7:38 a.m. ET Tuesday.
RYTELO Anchors The Business
RYTELO, also called imetelstat, targets telomerase, an enzyme malignant blood cells use to continue dividing. Its U.S. approval covers adults with lower-risk myelodysplastic syndromes—blood cancers—whose anemia requires transfusions and who cannot take certain anemia drugs or have not responded, or stopped responding, to them.
Geron launched RYTELO in the U.S. in June 2024. European Commission approval followed in March 2025, covering the 27 European Union member states as well as Iceland, Norway and Liechtenstein. The company plans to use third parties to commercialize the drug in the EU.
Geron's 2025 annual report described a U.S. sales team with more than 60 key account managers and regional staff. Outside the U.S., named patient programs with distributor Tanner Pharma also provide access, with minimal revenue to date.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: GERON CORP (GERN) — SEC EDGAR
- What Investors Got Wrong About Geron Before The Drop — Yahoo Finance
- Geron Corporation (NASDAQ:GERN) : Cases :: Law360 — law360.com
- Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo Finance — Yahoo Finance